[Ximelagatran, an oral thrombin inhibitor without the need for regular monitoring of the anticoagulant status].
In two recent clinical trials, the effectiveness of ximelagatran, an oral thrombin inhibitor, was demonstrated as anticoagulant therapy for patients with atrial fibrillation and as secondary prophylaxis for patients following a myocardial infarction, respectively. This may be of relevance for the often life-long treatment of patients with anticoagulants, as with ximelagatran frequent monitoring of the anticoagulant status is not necessary, in contrast to treatment with warfarin-like drugs.